ScripRoivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com
ScripRoivant’s confidence in Immunovant’s neonatal fragment crystallizable receptor (FcRn) inhibitor IMVT-1402 has only grown, Roivant CEO Matt Gline said, since the company and its subsidiary announced ea
ScripRoivant subsidiary Immunovant announced positive Phase III data for its neonatal fragment crystallizable receptor (FcRn) inhibitor batoclimab in myasthenia gravis (MG), but a key piece of the update i
ScripPfizer/Arvinas’s VERITAC-2 Study Of Vepdegestrant In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD)